Explore the words cloud of the InSilc project. It provides you a very rough idea of what is the project "InSilc" about.
The following table provides information about the project.
Coordinator |
IDRYMA TECHNOLOGIAS KAI EREVNAS
Organization address contact info |
Coordinator Country | Greece [EL] |
Project website | https://insilc.eu/ |
Total cost | 5˙839˙656 € |
EC max contribution | 5˙839˙656 € (100%) |
Programme |
1. H2020-EU.3.1.5. (Methods and data) |
Code Call | H2020-SC1-2017-CNECT-2 |
Funding Scheme | RIA |
Starting year | 2017 |
Duration (year-month-day) | from 2017-11-01 to 2020-10-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | IDRYMA TECHNOLOGIAS KAI EREVNAS | EL (IRAKLEIO) | coordinator | 822˙365.00 |
2 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | NL (ROTTERDAM) | participant | 746˙830.00 |
3 | POLITECNICO DI MILANO | IT (MILANO) | participant | 603˙130.00 |
4 | NATIONAL UNIVERSITY OF IRELAND GALWAY | IE (Galway) | participant | 566˙155.00 |
5 | UNIVERSITY OF LEEDS | UK (LEEDS) | participant | 559˙580.00 |
6 | CBSET, INC | US (LEXINGTON) | participant | 503˙211.00 |
7 | FEOPS NV | BE (GENT) | participant | 409˙330.00 |
8 | ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO | RS (KRAGUJEVAC) | participant | 363˙080.00 |
9 | CONSIGLIO NAZIONALE DELLE RICERCHE | IT (ROMA) | participant | 343˙705.00 |
10 | BOSTON SCIENTIFIC LIMITED | IE (GALWAY) | participant | 305˙580.00 |
11 | PANEPISTIMIO IOANNINON | EL (IOANNINA) | participant | 259˙355.00 |
12 | MEDIOLANUM CARDIO RESEARCH SRL | IT (MILANO) | participant | 259˙330.00 |
13 | THE UNIVERSITY OF SHEFFIELD | UK (SHEFFIELD) | participant | 98˙000.00 |
The aim of InSilc is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches to simulate their implantation performance in the individual cardiovascular physiology. The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for simulating the drug-eluting BVS mechanical behaviour, the deployment and degradation, the fluid dynamics in the micro- and macroscale, and the myocardial perfusion, for predicting its interaction with the vascular wall in the short- and medium/long term. InSilc goes beyond the design and development of ISCT and lays on the generation of in-silico models for obtaining quick and informed answers to several “What if” scenarios. “Virtual” patients would be given a “virtual” drug-eluting BVS, for observing the performance of the scaffold, assess and quantify the intended effect, with a deeper understanding than normal trials can provide. By integrating the information obtained from different in-silico predictive models, InSilc will: (i) assist in the development, assessment and optimization of the drug-eluting BVS and deliver accurate and reliable information to the Stent Biomedical Industry, (ii) assist the interventional Cardiologists in improving the surgical process of drug-eluting BVS implantation, support them in the clinical assessment and reduce the complications of suboptimal scaffold performance. By introducing computer simulations for establishing the safety and efficacy of drug-eluting BVS, InSilc aims to lower development costs and shorten time-to-market, reduce, refine, and partially replace human clinical trials through a more effective human clinical trials design, reduce the need for animal testing and result in a significant reduction of the associated direct and indirect costs.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Georgia S. Karanasiou; Nikolaos S. Tachos; Antonios Sakellarios; Claire Conway; Giancarlo Pennati; Lorenza Petrini; Lampros K. Michalis; Elazer R. Edelman; Dimitrios I. Fotiadis In Silico analysis of stent deployment - effect of stent design published pages: , ISSN: , DOI: 10.5281/zenodo.2018351 |
2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) | 2019-08-07 |
2019 |
Sarrami-Foroushani, Ali; Lassila, Toni; Hejazi, Seyed Mostafa; Nagaraja, Sanjoy; Bacon, Andrew; Frangi, Alejandro F. A computational model for prediction of clot platelet content in flow-diverted intracranial aneurysms published pages: , ISSN: 0021-9290, DOI: 10.5281/zenodo.2671637 |
Journal of Biomechanics | 2019-08-07 |
2018 |
GEORGIA KARANASIOU; GEORGE RIGAS; SAVVAS KYRIAKIDIS; NIKOLAOS TACHOS; ANTONIS SAKELLARIOS; DIMITRIOS FOTIADIS InSilc: 3D Reconstruction and plaque characterization tool published pages: , ISSN: , DOI: 10.5281/zenodo.2017989 |
2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) | 2019-08-07 |
2018 |
Arso M. Vukicevic, Serkan Çimen, Nikola Jagic, Gordana Jovicic, Alejandro F. Frangi, Nenad Filipovic Three-dimensional reconstruction and NURBS-based structured meshing of coronary arteries from the conventional X-ray angiography projection images published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-19440-9 |
Scientific Reports 8/1 | 2019-08-07 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INSILC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INSILC" are provided by the European Opendata Portal: CORDIS opendata.
EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.
Read MoreARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY
Read More